Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential
Executive Summary
Bristol-Myers Squibb and AstraZeneca will need to design a precedent-setting cardiovascular outcomes study for saxagliptin before the drug will be approved by the agency
You may also be interested in...
Bristol/AstraZeneca Roll Out Onglyza Post-Market Cardio Study
The Phase IV commitment to study cardio risk is part of saxagliptin's approval, but the partners are also looking for data to support a claim of cardioprotective effect.
Saxagliptin Review Deadline Pushed Back; Approval Chances Still Look Good
FDA is extending the user fee goal date for action on Bristol-Myers Squibb/AstraZeneca's DPP-4 inhibitor antidiabetic Onglyza (saxagliptin) to July 30
Saxagliptin Review Deadline Pushed Back; Approval Chances Still Look Good
FDA is extending the user fee goal date for action on Bristol-Myers Squibb/AstraZeneca's DPP-4 inhibitor antidiabetic Onglyza (saxagliptin) to July 30